Solventum Corp (SOLV)
UndervaluedFundamental
64
मूल्य
$86.85
मार्केट कैप
$15.24B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$8.31B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$1.43B
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-10M
कुल इक्विटी
$5.05B
कुल देनदारियाँ
$9.24B
Current Ratio
1.02
Interest Coverage
-
Debt/EBITDA
1.98
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$126.13
वर्तमान मूल्य
$86.85
Margin of Safety
+31.1%
Fair Value सीमा
$81.98 - $170.27
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
10.76
ROE
30.8%
P/B Ratio
3.13
P/FCF
-
Gross Margin
54.7%
ROIC
15.5%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
15.5%
WACC
6.3%
ROIC − WACC
+9.2 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (15)
- EPS shows upward trend
- Price CAGR 15.07%
- ROIC 15.5%
- Gross Margin 54.7%
- Debt/Equity ratio
- Operating Margin 25.0%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 29.0%
- Analyst Consensus 59% Buy
- Earnings Surprise avg 11.0%
- Share Dilution 1.0%
- Net Margin Trend 17.3% vs 4.5%
- Piotroski F-Score 7/9
फेल (7)
- EPS CAGR 4.51%
- P/B Ratio 3.13
- Positive Free Cash Flow
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Earnings Quality (OCF/NI) 0.15
अनुपलब्ध (6)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर संख्या स्थिर है
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 58 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 55 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 50 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 58 |
| Ms. Heather L. Knight | Chief Commercial Officer | 53 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 49 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | - |
| Ms. Kate Dobbs | Chief Communications & Corporate Marketing Officer | - |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 55 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 52 |
Audit जोखिम
10
बोर्ड जोखिम
3
मुआवजा जोखिम
8
शेयरधारक अधिकार जोखिम
6
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-27
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-05
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-08-05
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for SOLV, sourced from Markets Gazette.
- 2/26/2026NEUTRALSolventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.
via Markets Gazette